MOLECULAR APPROACHES TO CANCER IMMUNOTHERAPY

要求为美国科学家组织的一次科学会议提供支助， 癌症研究协会。 会议题为“分子 癌症免疫治疗方法”将在格罗夫公园旅馆举行 1993年11月7日至11日在北卡罗来纳州阿什维尔举行。会议主席是 首席研究员拉尔夫·A博士赖斯菲尔德 会议的主要目标是提供一个深入的评价 关于癌症免疫疗法的已知知识， 对细胞表面抗原或外源性抗原的免疫应答，以及 DNA技术和生物技术迅速发展的重要性， 以及适当考虑在谅解方面取得的进展， 是什么触发了免疫细胞的活动。 29位杰出的科学家将发表演讲， 将有机会展示他们自己的作品。 会议将汇集一批世界级的专家， 癌症免疫治疗的不同领域，其工作表明 令人振奋的癌症治疗新方法 这些研究 取得的实质性进展使发展成为可能， 在过去的十年中，在三个主要研究领域：首先，有 在更好地理解分子本质方面取得了巨大的进步 对细胞表面抗原或外源性抗原的免疫反应 与主要组织相容性复合体分子一起呈现。 第二，重组DNA技术的迅速发展， 生物技术作为一个整体，使获得大量的 分子定义的生物分子如单克隆抗体， 细胞因子和生长因子。 第三，我们的工作取得了进展， 了解是什么触发了免疫细胞的活动。 这些见解 导致了新的基因治疗方法，可以克服令人沮丧的 免疫防御系统无力科普人类癌症。 这将是一系列出色的会议中的第二十七次会议， 协会组织的特别会议。 主办方认为 它将为研究人员提供一个独特的机会， 快速发展的科学领域，以交流新的思想和发展 新的概念方法，他们的研究。

Support is requested for a scientific meeting organized by the American Association for Cancer Research. The conference, entitled "Molecular Approaches to Cancer Immunotherapy," will be held at the Grove Park inn in Asheville, NC, on November 7-11, 1993. The conference chairperson is the Principal investigator, Dr. Ralph A. Reisfeld. The major goals of the conference are to provide an in-depth evaluation of what is known about cancer immunotherapy, the molecular nature of the immune response to cell surface antigens or to exogenous antigens, and the significance of the rapid advances in DNA technologies and biotechnology, as well as the appropriate consideration of advances in the understanding of what triggers immune cell activity. Twenty-nine distinguished scientists will deliver talks, and registrants will have the opportunity to give poster presentations of their own work. The conference will bring together a group of world class experts in different areas of cancer immunotherapy whose work is indicative of the new and exciting approaches to cancer treatment. These research developments have been made possible by the substantial progress made during the last decade in three major research areas: First, there have been great strides towards a better understanding of the molecular nature of the immune response to cell surface antigens or to exogenous antigens presented in conjunction with major histocompatibility complex molecules. Second, the rapid advances in recombinant DNA technologies and in biotechnology as a whole have made it possible to obtain large amounts of molecularly defined biological molecules such as monoclonal antibodies, cytokines, and growth factors. Third, there have been advances in our understanding of what triggers immune cell activity. These insights have led to novel gene therapy approaches that may overcome the frustrating inability of the immune defense system to cope with human cancer. This will be the twenty-seventh meeting in an outstanding series of special conferences organized by the Association. The organizers believe that it will present a unique opportunity for investigators working in rapidly developing scientific areas to exchange new ideas and develop novel conceptual approaches to their research.